Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: Does age or family history matter?

Breast Cancer Research and Treatment

Volumn 129, Issue 1, 2011, Pages 211-219

  Lowery, Jan T ^a   Byers, Tim ^a   Kittelson, John ^a   Hokanson, John E ^a   Mouchawar, Judy ^b   Lewin, John ^c   Merrick, Dan ^d   Hines, Lisa ^e   Singh, Meenakshi ^f  

^a Food Science and Human Nutrition   (United States)

^b KAISER PERMANENTE   (United States)

^c Diversified Radiology of Colorado   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f STONY BROOK UNIVERSITY   (United States)

Author keywords

Biomarkers; Interval breast cancer; Tissue micro arrays

Indexed keywords

BIOCHEMICAL MARKER; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST SELF EXAMINATION; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FISHER EXACT TEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960835281     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1448-8     Document Type: Article

References (44)

1. PL Porter AY El-Bastawissi MT Mandelson, et al. 1999 Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers J Natl Cancer Inst 91 23 2020 2028 10580027 10.1093/jnci/91.23.2020 1:STN:280:DC%2BD3c%2FkvVSitg%3D%3D
2. FD Gilliland N Joste PM Stauber, et al. 2000 Biologic characteristics of interval and screen-detected cancers J Natl Cancer Inst 92 9 743 749 10793111 10.1093/jnci/92.9.743 1:STN:280:DC%2BD3c3lsFersQ%3D%3D (Pubitemid 30365535)
3. M Crosier D Scott RG Wilson CD Griffiths FE May BR Westley 2001 High expression of the trefoil protein TFF1 in interval breast cancers Am J Pathol 159 1 215 221 11438468 10.1016/S0002-9440(10)61687-2 1:CAS:528: DC%2BD3MXlslamurY%3D (Pubitemid 33704206)
4. MA Raja A Hubbard AR Salman 2001 Interval breast cancer: is it a different type of breast cancer? Breast 10 2 100 108 14965568 10.1054/brst.2000.0217 1:STN:280:DC%2BD2c%2Fns1ertA%3D%3D (Pubitemid 32390223)
5. CE Crane CG Luke JM Rogers PE Playford DM Roder 2002 An analysis of factors associated with interval as opposed to screen-detected breast cancers, including hormone therapy and mammographic density Breast 11 2 131 136 14965659 10.1054/brst.2001.0371 1:STN:280:DC%2BD2c%2Fns1Gnsw%3D%3D (Pubitemid 34679263)
6. HC Burrell DM Sibbering A Wilson, et al. 1996 Screening interval cancers: mammographic features and prognosis factors Radiology 199 3 811 817 8638010 1:STN:280:DyaK283itVGnug%3D%3D (Pubitemid 26157489)
7. PJ Klemi S Toikkanen O Rasanen I Parvinen H Joensuu 1997 Mammography screening interval and the frequency of interval cancers in a population-based screening Br J Cancer 75 5 762 766 9043038 10.1038/bjc.1997.135 1:STN:280:DyaK2s7psFKltw%3D%3D (Pubitemid 27091095)
8. WK Cowan B Angus JC Cray LG Lunt S Ramedan Al-Tamimi 2000 A study of interval breast cancer within the NHS breast screening programme J Clin Path 53 140 146 10767831 10.1136/jcp.53.2.140 1:STN:280:DC%2BD3c3jtVeltw%3D%3D (Pubitemid 30075059)
9. H Wang N Bjurstam H Bjorndal, et al. 2001 Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT Int Jr Cancer 94 594 598 10.1002/ijc.1511 1:CAS:528:DC%2BD3MXns1Gnu70%3D (Pubitemid 32982142)
10. RPR Groenendijk P Bult AM Noppen C Boetes TJM Ruers T Wobbes 2003 Mitotic activity in interval breast cancers Eur J Surg Oncol 29 29 31 12559073 10.1053/ejso.2002.1390 1:STN:280:DC%2BD3s%2FltVSitQ%3D%3D (Pubitemid 36181774)
11. K Collett IM Stefansson J Eide, et al. 2005 A basal epithelial phenotype is more frequent in interval breast cancers compared with screen-detected tumors Cancer Epidemiol Biomarkers Prev 14 5 1108 1112 15894660 10.1158/1055-9965.EPI- 04-0394 1:CAS:528:DC%2BD2MXktFCksLg%3D (Pubitemid 40656455)
12. CT Brekelmans JM van Gorp PH Peeters HJ Collette 1996 Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups Cancer 78 6 1220 1228 8826943 10.1002/(SICI)1097-0142(19960915)78: 6<1220::AID-CNCR8>3.0.CO;2-D 1:STN:280:DyaK28visVChsg%3D%3D (Pubitemid 26303887)
13. M Crosier D Scott RG Wilson CD Griffiths FE May BR Westley 1999 Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers Clin Cancer Res 5 10 2682 2688 10537329 1:CAS:528:DyaK1MXntlGltL0%3D (Pubitemid 29493939)
14. J Anttinen T Kuopio M Nykanen H Tirjjeki U Saari M Juhola 2003 Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers Anticancer Res 23 5 4213 4218 14666627 1:CAS:528:DC%2BD2cXkvV2k (Pubitemid 37474922)
15. K Collett IM Stefansson J Eide, et al. 2005 A basal epithelial phenotype is more frequent in interval breast cancers compared with screen-detected tumors Cancer Epidemiol Biomarker Prev 14 5 1108 1112 10.1158/1055-9965.EPI-04-0394 1:CAS:528:DC%2BD2MXktFCksLg%3D (Pubitemid 40656455)
16. MJ Van de Vijver YD He L Van't Veer, et al. 2002 A gene expression signature as a predictor of survival in breast cancer N Engl J Med 347 1999 2009 12490681 10.1056/NEJMoa021967 (Pubitemid 35461656)
17. MF Rimawi PB Shetty HL Weiss, et al. 2010 Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes Cancer 116 1234 1242 20082448 10.1002/cncr.24816
18. JT Lowery T Byers JE Hokanson J Kittelson J Lewin B Risendal M Singh J Mouchawar 2010 Complementary approaches to assessing risk factors for interval breast cancer Cancer Causes Control 68 21 8993 8997
19. AJ Nixon D Neeuberg DF Hayes 1994 Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer J Clin Oncol 12 888 894 8164038 1:STN:280:DyaK2c3hs12gtA%3D%3D (Pubitemid 24145313)
20. DS Buist PL Porter C Lehman SH Taplin E White 2004 Factors contributing to mammography failure in women aged 40-49 years J Natl Cancer Inst 96 19 1432 1440 15467032 10.1093/jnci/djh269 (Pubitemid 39429667)
21. M Agrup O Stal K Olsen S Wingren 2000 C-erbB-2 overexpression and survival in early onset breast cancer Breast Cancer Res Treat 63 23 29 11079156 10.1023/A:1006498721508 1:CAS:528:DC%2BD3cXot1Skurs%3D
22. DF Easton DT Bishop D Ford GP Crodkford 1993 Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The breast cancer linkage consortium Am J Hum Genet 52 678 701 8460634 1:CAS:528: DyaK2cXhtVemurs%3D (Pubitemid 23310135)
23. KA Phillips 2000 Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers J Clin Oncol 18 107 112
24. H Anton-Culver A Ziogas D Bowen, et al. 2003 The cancer genetics network: recruitment results and pilot studies Community Genet 6 3 171 177 15237201 10.1159/000078165 (Pubitemid 38916116)
25. A Hoos MJ Urist A Stojadinovic, et al. 2001 Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the exampl of human fibroblastic tumors Am J Pathol 158 4 1245 1251 11290542 10.1016/S0002-9440(10)64075-8 1:CAS:528:DC%2BD3MXjtVWhsLc%3D (Pubitemid 32281288)
26. KC Lear-Kaul HR Yoon BK Kleinschmidt-DeMasters L McGavran M Singh 2003 Her2-neu status in breast cancer metastasis to the central nervous system Arch Pathol Lab Med 127 11 1451 1457 14567724 1:CAS:528:DC%2BD3sXpsVCru70%3D (Pubitemid 37370391)
27. MC Cheang SK Chia D Voduc, et al. 2009 Ki67 index, Her2 status, prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 10 736 750 19436038 10.1093/jnci/djp082 1:CAS:528:DC%2BD1MXmtlyit74%3D
28. JD Emerson GA Colditz 1983 Use of stastical analysis N Eng J Med 309 709 713 10.1056/NEJM198309223091206 1:STN:280:DyaL3s3pslGhsQ%3D%3D
29. B Van Der Vegt J Wesseling R Pijnappel 2010 Aggressiveness of 'true' interval invasive ductal carcinomas of the breast in postmenopausal women Modern Pathology 23 629 636 20081807 10.1038/modpathol.2009.188
30. WR Bezwoda JD Esser R Danwey I Kessel MM Rad M Lange 1991 The value of estrogen and progesterone receptor determinations in advanced breast cancer Cancer 68 867 872 1855186 10.1002/1097-0142(19910815)68:4<867::AID- CNCR2820680432>3.0.CO;2-H 1:STN:280:DyaK3MzgvFSgsQ%3D%3D
31. Dickson RB, Lippman ME (1995) Molecular basis of breast cancer. In: Mendelsohn J, Howley PH, Israel MA (eds) The molecular basis of cancer, 2nd edn. WB Sanders Co., Philadelphia, PA
32. S Badve DJ Dabbs SJ Schnitt, et al. 2010 Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists Modern Pathology November 12 1 10
33. ML Burness TA Grushko OI Olopade 2010 Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 16 1 23 32 20164687 10.1097/PPO.0b013e3181d24fc1 1:CAS:528:DC%2BC3cXjvVKkt7Y%3D
34. JS Reis-Filho AN Tutt 2008 Triple negative tumours: a critical review Histopathology 52 1 108 118 18171422 10.1111/j.1365-2559.2007.02889.x 1:STN:280:DC%2BD1c%2FgsF2mtg%3D%3D (Pubitemid 350265179)
35. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. J Clin Oncol 24(36):5652-5657 (Pubitemid 46631305)
36. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California tumor registry Cancer 109 9 1721 1728 17387718 10.1002/cncr.22618 (Pubitemid 46668532)
37. CA Parise KR Bauer MM Brown V Caggiano 2009 Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor (HER2) among women with invasive breast cancer in California, 1999-2004 Breast J 15 6 593 602 19764994 10.1111/j.1524-4741. 2009.00822.x
38. Domingo L, Sala M, Servitja S et al (2010) Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes Control
39. J McCann PD Britton RML Warren G Hunnam 2001 Radiological peer review of interval cancers in the East Anglian breast screening programme: what are we missing? Jr Med Screen 8 2 77 82 10.1136/jms.8.2.77 1:STN:280: DC%2BD38%2FitlyltA%3D%3D (Pubitemid 32664888)
40. L Ma E Fishell B Wright W Hanna S Allan NF Boyd 1992 Case-control study of factors associated with failure to detect breast cancer by mammography J Natl Cancer Inst 84 781 785 1573665 10.1093/jnci/84.10.781 1:STN:280: DyaK383ktlCruw%3D%3D
41. LA Carey CM Perou CH Livasy, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina breast cancer study JAMA 295 21 2492 2502 16757721 10.1001/jama.295.21.2492 1:CAS:528:DC%2BD28XlsV2rtLw%3D (Pubitemid 43854964)
42. D Zhang M Salto-Tellez E Do TC Putti ES Kiay 2003 Evaluation of Her2/neu onogene status in breast tumors on tissue microarrays Hum Pathol 34 4 362 368 12733117 10.1053/hupa.2003.60 1:CAS:528:DC%2BD3sXjs1equro%3D (Pubitemid 36535020)
43. DJ Slamon GM Clark SG Wong WJ Levom A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D (Pubitemid 17231334)
44. K Gower-Thomas H Fielder L Branston S Greening H Beer C Rogers 2002 Reviewing interval cancers: time well spent? Clin Radiol 57 384 388 12014936 10.1053/crad.2001.0882